Article preview from IN VIVO - April, 2012
Since its spin-out from Tyco, Covidien has spent close to $5 billion acquiring public and privately held device companies, with more than $1 billion of that being spent just over the past six months. The string of purchases bulked up every one of Covidien’s existing medical device businesses. In the recent acquisition of superDimension, Covidien paid $300 million plus earn-outs for the maker of the iLogic system, which uses electromagnetic navigation bronchoscopy technology. The purchase means Covidien’s sales force will begin calling more on interventional pulmonologists, potentially creating an exit route for other pulmonary start-ups.
Article preview from IN VIVO - April, 2012
The only predictable part of Covidien PLC’s acquisition strategy is there’s no sign of it slowing down. For the past five years, since its spin-out from Tyco International Ltd., the multinational device company has spent close to $5 billion acquiring public and privately held device companies, with more than $1 billion of that being spent just over the past six months on privately held Barrx Medical Inc., Newport Medical Instruments Inc., Reverse Medical Corp., Oridion Systems Ltd., and superDimension Ltd.
The string of purchases bulked up every one of Covidien’s existing medical device businesses. For example, Covidien’s most recent acquisition of Oridion Systems, maker of products to measure patient breathing, will fit into its Oximetry and Monitoring business unit, which already had been bolstered by the past acquisitions of publicly traded Somanetics Corp. and Aspect Medical Systems Inc.[Meanwhile, the purchases of Vnus Medical Technologies Inc. and ev3 Inc., with the latter deal accounting for $2.5 billion of the capital spent, have successfully brought the company into the vascular and neurovascular markets.
Wall Street largely supports the strategy. Joanne K. Wuensch, medical device analyst for BMO Capital Markets, says Covidien has demonstrated that it knows how to spend well. With the exception of ev3, the acquired companies have been relatively small, so assimilation isn’t a challenge.
Continued...
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments